Display options
Cite
Starodubova ES, Isaguliants MG, Kuzmenko YV, et al. Fusion to the Lysosome Targeting Signal of the Invariant Chain Alters the Processing and Enhances the Immunogenicity of HIV-1 Reverse Transcriptase. Acta Naturae. 2014;6(1):61-8
Starodubova, E. S., Isaguliants, M. G., Kuzmenko, Y. V., Latanova, A. A., Krotova, O. A., & Karpov, V. L. (2014). Fusion to the Lysosome Targeting Signal of the Invariant Chain Alters the Processing and Enhances the Immunogenicity of HIV-1 Reverse Transcriptase. Acta naturae, 6(1), 61-8.
Starodubova, E S, et al. "Fusion to the Lysosome Targeting Signal of the Invariant Chain Alters the Processing and Enhances the Immunogenicity of HIV-1 Reverse Transcriptase." Acta naturae vol. 6,1 (2014): 61-8.
Starodubova ES, Isaguliants MG, Kuzmenko YV, Latanova AA, Krotova OA, Karpov VL. Fusion to the Lysosome Targeting Signal of the Invariant Chain Alters the Processing and Enhances the Immunogenicity of HIV-1 Reverse Transcriptase. Acta Naturae. 2014 Jan;6(1):61-8. PMID: 24772328; PMCID: PMC3999467.
Copy Download .nbib Format: NLM
Share it on

Acta Naturae. 2014 Jan;6(1):61-8.

Fusion to the Lysosome Targeting Signal of the Invariant Chain Alters the Processing and Enhances the Immunogenicity of HIV-1 Reverse Transcriptase.

Acta naturae

E S Starodubova, M G Isaguliants, Y V Kuzmenko, A A Latanova, O A Krotova, V L Karpov

Affiliations

  1. Engelhardt Institute of Molecular Biology Russian Academy of Sciences, Vaviolva str., 32, 119991, Moscow, Russia ; D.I. Ivanovsky Institute of Virology, Ministry of Health of the Russian Federation, 123098, Moscow, Russia.
  2. D.I. Ivanovsky Institute of Virology, Ministry of Health of the Russian Federation, 123098, Moscow, Russia ; Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, 17177, Stockholm, Sweden.
  3. Engelhardt Institute of Molecular Biology Russian Academy of Sciences, Vaviolva str., 32, 119991, Moscow, Russia.

PMID: 24772328 PMCID: PMC3999467

Abstract

Intracellular processing of the antigen encoded by a DNA vaccine is one of the key steps in generating an immune response. Immunization with DNA constructs targeted to the endosomal-lysosomal compartments and to the MHC class II pathway can elicit a strong immune response. Herein, the weakly immunogenic reverse transcriptase of HIV-1 was fused to the minimal lysosomal targeting motif of the human MHC class II invariant chain. The motif fused to the N-terminus shifted the enzyme intracellular localization and accelerated its degradation. Degradation of the chimeric protein occurred predominantly in the lysosomal compartment. BALB/c mice immunized with the plasmid encoding the chimeric protein demonstrated an enhanced immune response, in the form of an increased antigen-specific production of Th1 cytokines, INF-γ and IL-2, by mouse splenocytes. Moreover, the majority of the splenocytes secreted both cytokines; i.e., were polyfunctional. These findings suggest that retargeting of the antigen to the lysosomes enhances the immune response to DNA vaccine candidates with low intrinsic immunogenicity.

Keywords: DNA immunization; T-helper immune response; antigen processing; invariant chain; reverse transcriptase

References

  1. Curr Opin Immunol. 2007 Jun;19(3):315-9 - PubMed
  2. Annu Rev Immunol. 2000;18:927-74 - PubMed
  3. J Immunol. 2008 Oct 1;181(7):4955-64 - PubMed
  4. Nat Rev Immunol. 2011 Nov 11;11(12):823-36 - PubMed
  5. Proc Natl Acad Sci U S A. 1991 Jul 15;88(14):5998-6002 - PubMed
  6. Mol Ther. 2009 Sep;17(9):1637-42 - PubMed
  7. Vaccine. 2009 Jan 7;27(2):184-6 - PubMed
  8. Methods Mol Biol. 2004;284:67-77 - PubMed
  9. J Cell Sci. 1994 Jul;107 ( Pt 7):2021-32 - PubMed
  10. Protein Expr Purif. 2006 Jul;48(1):14-23 - PubMed
  11. Immunobiology. 2011 Apr;216(4):505-12 - PubMed
  12. Vaccine. 2006 May 22;24(21):4541-7 - PubMed
  13. J Cell Sci. 1993 Nov;106 ( Pt 3):831-46 - PubMed
  14. FEBS Lett. 1999 Mar 26;447(2-3):232-6 - PubMed
  15. Vaccine. 2009 Jul 30;27(35):4840-9 - PubMed
  16. Gene Ther. 2001 Mar;8(6):487-93 - PubMed
  17. J Cell Biol. 1994 Jul;126(2):317-30 - PubMed
  18. Vaccine. 2010 Feb 23;28(8):1975-86 - PubMed
  19. AIDS Res Hum Retroviruses. 2000 Sep 1;16(13):1269-80 - PubMed
  20. J Biol Chem. 1992 Jul 25;267(21):14654-61 - PubMed
  21. Nature. 2006 Jun 15;441(7095):890-3 - PubMed
  22. Curr Opin Virol. 2011 Oct;1(4):233-40 - PubMed
  23. Eur J Immunol. 1994 Jul;24(7):1496-502 - PubMed
  24. Intervirology. 2000;43(4-6):288-93 - PubMed
  25. AIDS Res Hum Retroviruses. 2004 Feb;20(2):191-201 - PubMed
  26. J Immunol. 1998 Dec 15;161(12):6532-6 - PubMed
  27. PLoS One. 2012;7(9):e45267 - PubMed
  28. Immunol Rev. 1999 Dec;172:87-96 - PubMed
  29. Mol Biol (Mosk). 1991 Sep-Oct;25(5):1248-57 - PubMed
  30. J Infect Dis. 2008 Nov 15;198(10):1482-90 - PubMed
  31. Annu Rev Immunol. 1997;15:821-50 - PubMed
  32. Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11671-5 - PubMed
  33. J Immunol. 2008 Mar 1;180(5):3339-46 - PubMed
  34. J Immunol. 2001 Mar 1;166(5):3061-6 - PubMed
  35. Immunology. 2002 Mar;105(3):252-62 - PubMed
  36. Nat Med. 2007 Jul;13(7):843-50 - PubMed
  37. Eur J Cell Biol. 2006 Jun;85(6):457-67 - PubMed
  38. Mol Ther. 2006 Feb;13(2):310-9 - PubMed
  39. J Immunol. 2001 Apr 1;166(7):4627-33 - PubMed
  40. Gene Ther. 1999 Nov;6(11):1826-34 - PubMed
  41. Clin Vaccine Immunol. 2007 Mar;14(3):304-11 - PubMed

Publication Types